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onstantine L. Athanasuleas, MD,* Gerald D. Buckberg, MD,† Alfred W. H. Stanley, MD,*
illiam Siler, PHD,* Vincent Dor, MD,‡ Marisa Di Donato, MD,§ Lorenzo Menicanti, MD,
ergio Almeida de Oliveira, MD,¶ Friedhelm Beyersdorf, MD,# Irving L. Kron, MD,**
isayoshi Suma, MD,†† Nicholas T. Kouchoukos, MD,‡‡ Wistar Moore, MD,§§
atrick M. McCarthy, MD,  Mehmet C. Oz, MD,¶¶ Francis Fontan, MD,## Meredith L. Scott, MD,§§
evin A. Accola, MD,§§ and the RESTORE Group
irmingham, Alabama; Los Angeles, California; Monte Carlo, Monaco; Florence and Milan, Italy; Sao Paulo,
razil; Freiburg, Germany; Charlottesville, Virginia; Kanagawa, Japan; St. Louis, Missouri; Orlando, Florida;
leveland, Ohio; New York, New York; and Bordeaux, France
OBJECTIVES The purpose of this study was to test how surgical ventricular restoration (SVR) affects early
and late survival in a registry of 1,198 post-anterior infarction congestive heart failure (CHF)
patients treated by the international Reconstructive Endoventricular Surgery returning
Torsion Original Radius Elliptical shape to the left ventricle (RESTORE) team.
BACKGROUND Congestive heart failure may be caused by late left ventricular (LV) dilation after anterior
infarction. The infarcted segment is often akinetic rather than dyskinetic because early
reperfusion prevents transmural necrosis. Previously, only dyskinetic areas were treated by
operation. Surgical ventricular restoration reduces LV volume and creates a more elliptical
chamber by excluding scar in either akinetic or dyskinetic segments.
METHODS The RESTORE group applied SVR to 1,198 post-infarction patients between 1998 and
2003. Early and late outcomes were examined, and risk factors were identified.
RESULTS Concomitant procedures included coronary artery bypass grafting in 95%, mitral valve repair
in 22%, and mitral valve replacement in 1%. Overall 30-day mortality after SVR was 5.3%
(8.7% with mitral repair vs. 4.0% without repair; p  0.001). Perioperative mechanical
support was uncommon (9%). Global systolic function improved postoperatively. Ejection
fraction (EF) increased from 29.6  11.0% preoperatively to 39.5  12.3% postoperatively
(p  0.001). The left ventricular end-systolic volume index (LVESVI) decreased from 80.4
 51.4 ml/m2 preoperatively to 56.6  34.3 ml/m2 postoperatively (p  0.001). Overall
five-year survival was 68.6  2.8%. Logistic regression analysis identified EF 30%,
LVESVI 80 ml/m2, advanced New York Heart Association (NYHA) functional class, and
age75 years as risk factors for death. Five-year freedom from hospital readmission for CHF
was 78%. Preoperatively, 67% of patients were NYHA functional class III or IV and
postoperatively, 85% were class I or II.
CONCLUSIONS Surgical ventricular restoration improves ventricular function and is highly effective therapy in
the treatment of ischemic cardiomyopathy with excellent five-year outcome. (J Am Coll
Cardiol 2004;44:1439–45) © 2004 by the American College of Cardiology Foundationi
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she etiology of congestive heart failure (CHF) is coronary
rtery disease in approximately two-thirds of cases. The
ajority of these patients have experienced myocardial
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eccepted July 6, 2004.nfarction (1). Despite successful early reperfusion, late left
entricular (LV) dilation develops in 20% of patients and
eads to CHF (2,3). Myocardial necrosis progresses sequen-
ially in the untreated transmural infarction from endocar-
ium to epicardium (4). Early reperfusion alters the infarc-
ion process by sparing the epicardial layer and preventing
hin-walled dyskinetic aneurysm formation. The reperfused
nfarcted myocardium retains its thickness and normal
picardial appearance, resulting in an akinetic segment with
arying degrees of mid-myocardial and epicardial fibrosis.
he remote non-infarcted myocardium undergoes changes
n volume and shape during the course of “ventricular
emodeling.” As the ventricle enlarges, its normal elliptical
hape becomes spherical and global systolic function wors-
ns, resulting in CHF (5). The prognosis of patients with
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SVR for Ischemic Dilated Cardiomyopathy October 6, 2004:1439–45schemic cardiomyopathy is more closely related to LV
olume rather than to ejection fraction (EF) (6).
The new term “surgical ventricular restoration” (SVR)
ncludes operative methods that reduce LV volume and
restore” ventricular elliptical shape (7–9). Excision of a
hin-walled aneurysm with direct closure is an early method
f SVR first described by Cooley et al. (10,11) and modified
ver the years. This operation is rarely performed currently
ecause early reperfusion spares epicardial muscle, resulting
n regional thick-walled akinesia rather than thin-walled
yskinesia. Dor (12) recognized that the adverse effects of
emodeling on the remote non-infarcted myocardium were
imilar for akinesia and dyskinesia and was the first to utilize
he endocardial patch plasty procedure for both morpholo-
ies. Dor’s (12) operation improves systolic function and
ew York Heart Association (NYHA) functional class (13).
owever, the operation is not widespread because surgeons
ave been unwilling to exclude the akinetic normal-
ppearing segments often encountered after early reperfu-
ion. Instead, coronary artery bypass grafting (CABG) is
erformed and the non-functioning akinetic muscle seg-
ent containing deeper scar is left undisturbed.
The Reconstructive Endoventricular Surgery returning
orsion Original Radius Elliptical shape to the left ventricle
RESTORE) group is a team of cardiologists and surgeons
rom 12 centers on four continents: six in the U.S., four in
urope, one in South America, and one in Asia (Appendix).
he following sections report on the RESTORE SVR
egistry with five-year follow-up and provide an update of
ur previous three-year findings in 439 patients (14).
ETHODS
he SVR was performed in 1,198 patients between 1998
nd 2003. Inclusion criteria were previous anterior myocar-
ial infarction, significant ventricular dilation (left ventric-
lar end-systolic volume index [LVESVI]60 ml/m2), and
regional asynergic (non-contractile) LV circumference of
35%. Patients were in NYHA functional class I in 9%,
lass II in 22%, class III in 40%, and class IV in 29% of
ases. The small percentage of patients in class I underwent
VR while undergoing CABG or mitral repair as the
rimary operative indication, because LV volume exceeded
0 ml/m2. Echocardiography, ventriculography, or mag-
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
CABG  coronary artery bypass grafting
CHF  congestive heart failure
EF  ejection fraction
LV  left ventricular
LVAD  left ventricular assist device
LVESVI  left ventricular end-systolic volume index
NYHA  New York Heart Association
SVR  surgical ventricular restorationetic resonance imaging was used to confirm the asynergic vegment and calculate EF. The LVESVI was determined by
entriculography or magnetic resonance imaging. Institu-
ional review board approval was not obtained because the
nvestigators considered the operation an established ther-
py based on the acceptance of endoventricular circular
atch plasty and the reported outcomes of Dor et al. (15).
Anteroseptal, apical, and anterolateral LV scarred seg-
ents were identified and excluded by an intracardiac patch
r direct closure. The operation is illustrated in Figure 1.
atients were placed on cardiopulmonary bypass with mod-
rate hypothermia (approximately 34°C). Hearts were pro-
ected with warm and cold-blood cardioplegia during cor-
nary grafting and/or mitral procedures. The ventricular
estoration portion of the operation was performed during
ardioplegia-arrested heart by about half of the surgeons,
nd in the open-beating heart by the others. Postoperative
F and volumes were obtained before hospital discharge.
ollow-up NYHA functional class was obtained during
hysician visit or by telephone interview.
tatistics. Analysis of survival and readmission probabili-
ies versus volume, EF, and age were carried out using
aplan-Meier survival analysis to properly account for
atients lost to follow-up. A similar analysis was used to
etermine the effect of mitral valve repair, replacement, and
eadmission. Times were taken as times to first readmission
or readmitted patients, time to death for non-readmitted
atients who died, and time to last follow-up for all others.
atients lost to follow-up were removed from the study
censored) for Kaplan-Meier survival analysis as of the date
f last follow-up. Data comparisons used the general linear
odel for numeric data and logistic regression for categor-
cal data. The SAS Institute JMP 4.0 statistical package was
sed for all tests.
ESULTS
aseline characteristics. Patient age ranged from 25 to 89
ears with a mean of 63  11 years. The interval between
nterior infarction and SVR procedure averaged 4.4 years.
ean NYHA functional class was 2.9 preoperatively with
% of patients in class I, 22% in class II, 40% in class III,
nd 29% in class IV. Akinesia was present in 66% of cases
nd dyskinesia in 34%. Larger ventricular volumes were
oted in patients with akinetic segments. Among the
entricles with LVESVI 80 ml/m2, akinesia was present
n 73.3% and dyskinesia in 26.7%.
Concomitant procedures included CABG in 95%, mitral
alve repair in 22%, and mitral valve replacement in 1%.
atients undergoing mitral valve procedures had reduced
F and larger ventricles compared with patients in whom
o mitral procedure was performed. If EF was30%, mitral
alve procedures were performed in 33.3% versus 15.0% in
atients whose EF was 30% (p  0.0001). Among
atients with LVESVI 80 ml/m2, mitral procedures were
ore common as compared with patients with smallerolumes (34.1% vs. 21.1%, p  0.0001).
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October 6, 2004:1439–45 SVR for Ischemic Dilated Cardiomyopathyarly outcome. Global systolic function improved postop-
ratively. The EF, measured in 1,118 patients before dis-
harge from the hospital, increased from 29.6  11.0%
reoperatively to 39.5 12.3% postoperatively (p 0.001).
oth preoperative and postoperative EF were significantly
ess for patients undergoing mitral valve repair. There was
o difference between the groups in improvement in EF
Table 1).
The LVESVI, obtained in 671 patients, was reduced
rom 80.4  51.4 ml/m2 preoperatively to 56.6  34.3
l/m2 postoperatively (p  0.001). Normal LVESVI is 24
10 ml/m2 (16). Patients undergoing mitral valve repair
ad significantly larger hearts preoperatively than those with
o mitral valve repair. There was no difference in postop-
rative LVESVI between the groups. Improvement in
VESVI was significantly greater in patients undergoing
itral valve repair (Table 2).
Thirty-day mortality after SVR was 5.3%, and it was
igher among patients undergoing concomitant mitral valve
epair (8.7%) versus patients in whom no mitral valve
rocedure was required (4.0%, p  0.001). Perioperative
echanical support was uncommon; intra-aortic balloon
umping was used in 8.2%, left ventricular assist device
igure 1. (A) Incision into the scar of the dilated ventricle. (B) Placement o
atch. LV  left ventricle.
able 1. LVESVI (ml/m2) and Mitral Valve Repair
No Mitral
Repair
Mitral
Repair
p
Value
reoperative 76.3 89.4  0.006
ostoperative 56.0 55.8 NS
hange 20.3 33.6  0.002VESVI  left ventricular end-systolic volume index. ELVAD) in 0.7%, and extracorporeal membrane oxygen-
tion in 0.3%.
To assess inter-institutional differences in outcome, the
enters were arranged in order of increasing preoperative
isk, as determined by logistic regression of a combination of
reoperative NYHA functional class, EF, LVESVI, and age
n survival. Incomplete data excluded some patients from
his analysis. There was a nearly linear relationship between
isk and five-year survival for all centers for which mean-
ngful risks could be calculated.
ate outcome. Overall five-year survival was 68.6  2.8%,
alculated by the Kaplan-Meier product-limit method (Fig.
). Mean time to death or loss to follow-up was 1.85 1.45
ears; at the end of five years, 22 patients remained in the
tudy. Survival at five years was better in the group of
atients that had dyskinetic as compared with akinetic
orphology (80% vs. 65%; p  0.001) (Fig. 3). Logistic
egression analysis identified risk factors for death at any
ime after surgery. These included preoperative EF 30%,
VESVI 80 ml/m2, advanced NYHA functional class,
nd age 75 years. Patients with EF 30% had survival
6.7  3.2% as compared with 63.8  3.9% for those with
F 30% (Fig. 4). Patients with EF 40% had survival
ure to exclude the scarred segment. (C) Completed repair with endocardial
able 2. EF (%) and Mitral Valve Repair
No Mitral
Repair
Mitral
Repair
p
Value
reoperative 31.0 25.4  0.0001
ostoperative 41.3 34.0  0.0001
hange 10.3 9.3 NSf a sutF  ejection fraction.
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SVR for Ischemic Dilated Cardiomyopathy October 6, 2004:1439–453.0  4.0% as compared with 67.4  3.0% for those with
F 40% (p  0.001). Patients with LVESVI 80 ml/m2
ad survival 79.4 3.3% as compared with 67.2 3.2% for
hose with hearts 120 ml/m2 (p  0.001) (Fig. 5).
reoperative NYHA functional class was associated with
ong-term survival. At five years, survival was 94.5  2.7%
n NYHA functional class I, 87.2 3.3% in class II, 69.9
.7% in class III, and 49.7  5.8% in class IV (p  0.001)
Fig. 6).
Mitral valve procedures were performed more commonly
n patients with larger ventricles and reduced EF. Mortality
t 30 days was higher in patients who underwent concom-
tant mitral repair (9.1%) as compared with those in whom
o mitral valve procedure was performed (4%; p  0.001).
owever, at five years, the survival curves were not different
etween patients who underwent repair and those who did
ot (68.7  3.9% vs. 70.8  3.3%). Mitral valve replace-
ent was rare (30 patients, 1%) and was performed early
n the registry. These patients had extensive areas of remote
uscle scar precluding simple annuloplasty to correct mitral
egurgitation.
Freedom from readmission to the hospital for CHF was
8%. The NYHA functional class improved from a mean of
.9 preoperatively to 1.7 postoperatively. Preoperatively,
7% of patients had NYHA functional class III or IV
ymptoms (39% class III, 28% class IV). Postoperatively,
5% were functional class I or II (48% class I, 37% class II).
VR in the elderly. Age was also a risk factor. Among all
atients operated on, 12.4% (149) were 75 years old.
Figure 2. Overall five-year survival.
igure 3. Survival based upon chamber morphology: dyskinesia versus
rkinesia.oncomitant procedures included coronary bypass in 98%,
itral valve repair in 17%, and replacement in 4%. Mortality
0 days after operation was 13% and higher than in younger
atients. Postoperative hemodynamic support with intra-
ortic balloon pumping was required in 13%. The EF
mproved from 31% preoperatively to 39% postoperatively
p  0.001). The LVESVI was reduced from 88 ml/m2 to
0 ml/m2 (p  0.001). Overall five-year survival in the
lderly was 63% and related to preoperative EF (50% if
reoperative EF 30% and 73% if EF 30%; p  0.001).
mong elderly patients undergoing concomitant CABG,
he five-year survival was 71% compared with 55% among
atients undergoing simultaneous mitral valve procedures.
he NYHA functional class III and IV was present in 70%
f patients preoperatively and in 20% postoperatively. Mean
YHA functional class improved from 3.0 to 1.9. Hospital
eadmission for CHF at five years was 15%.
ISCUSSION
emodeling after infarction enlarges chamber diameter and
ncreases wall tension by Laplace’s law. The augmented wall
tress results in increased oxygen consumption, decreased
ubendocardial blood flow, and reduced systolic shortening.
hite et al. reported that LV volume was more predictive
f survival than EF after infarction (6). Investigators in the
lobal Utilization of Streptokinase and t-PA for Occluded
oronary Arteries (GUSTO I) trial confirmed this and
howed that LVESVI 40 ml/m2 after infarction was
ssociated with high CHF rates and poor long-term survival
3). The SVR reshapes the remodeled LV and significantly
educes chamber volume.
Ventricular shape in dilated cardiomyopathy is also an
mportant determinant of function. As the enlarging LV
hanges from elliptical to spherical, normal systolic torsion
s reduced. The myofibrils of the spherical LV are shifted
way from their normal oblique axis toward a more trans-
erse direction. The normal myofibril shortening of 15%
enerates a global EF of only 30% in spherical ventricles, as
ompared with an EF of 60% in elliptical ventricles with
atural torsion (17). The circumferential radius of curvature
ncreases after infarction with loss of regional EF in the
Figure 4. Survival based upon preoperative ejection fraction.emote non-infarcted myocardium (18). The Dor procedure
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October 6, 2004:1439–45 SVR for Ischemic Dilated Cardiomyopathymproves global systolic function by increasing regional
unction in remote non-infarcted segments (19). Postoper-
tively, LV shape becomes more elliptical in systole than it
as in diastole (20).
In this RESTORE registry, SVR was used to correct LV
eometry in all cases. Concomitant procedures included
ABG in 95% and mitral valve intervention in 23%. Thus,
he three pathologic components contributing to CHF—
he ventricle, vessel, and valve—were all surgically corrected.
ur integrated approach resulted in an overall five-year
urvival of approximately 70% and a rehospitalization for
HF of 22%. These results can be contrasted to current
pproaches including medical therapy, CABG alone,
ABG with mitral intervention, ventricular assist devices,
nd transplantation.
edical therapy. Angiotensin-converting enzyme (ACE)
nhibitors increase survival among NYHA functional class
V CHF patients as shown in the Cooperative North
candinavian Enalapril Survival Study (CONSENSUS)
rial; however, only 64% survived to one year (21). Although
he Carvedilol Prospective Randomized Cumulative Sur-
ival (COPERNICUS) trial demonstrated an advantage of
dding carvedilol to ACE drugs in patients with EF 25%,
urvival at 28 months was 72% (22). Recently, the Carve-
ilol or Metoprolol European Trial (COMET) trial exam-
ned the efficacy of carvedilol in NYHA functional class III
48%) and IV (3%) patients with a mean EF of 26%.
urvival at five years was 66% in the carvedilol treated group
23). In the Carvedilol and ACE Inhibitor Remodeling
ild Heart Failure EvaluatioN (CARMEN) trial, the
ajority of patients were NYHA functional class II (60% to
0%) and there were none in class IV. Event-free mortality
r hospitalization was approximately 75% at two years with
arginal reduction of LVESVI (7 ml/m2) and EF improve-
ent of 3.5% (24). Recently, spironolactone was added to
CE and beta-blocker therapy in the Randomized Aldac-
one Evaluation Study (RALES) trial among patients with
F 35%. Pre-treatment class was not reported, but the
wo-year survival was 65% in the treated group versus 54%
n the placebo group (25).
igure 5. Survival based upon preoperative left ventricular end-systolic
olume index.In contrast to the above-cited trials, our RESTORE uegistry provides five-year follow-up in patients whose
YHA functional class was III or IV in 67% of cases.
ystolic function was measured by EF and ventricular
olume. Both showed dramatic improvement. Rehospital-
zation was very low in a high-risk patient population.
oronary revascularization. Coronary artery bypass graft-
ng can be safely carried out in patients with reduced systolic
unction because of improved methods of myocardial pro-
ection; however, the five-year survival of patients with EF
35% is 50% to 65% (26–29). The CABG alone is not very
ffective when ventricular dilation occurs. In one study,
ABG mortality was 27% if LV end-diastolic diameter was
81 mm (30). Moreover, CHF symptoms are common
fter CABG for ischemic cardiomyopathy. Yamaguchi’s
nalysis of CABG for patients with EF 30% showed that
utcome correlated with preoperative LVESVI. The five-
ear survival was 54% if the preoperative LVESVI was
100 ml/m2 compared with 85% if LVESVI was 100
l/m2. Congestive heart failure at five years was seen in
9% of patients with the larger hearts versus 15% with the
maller ones (31). Luciani et al. reviewed 167 patients who
nderwent CABG with a mean EF of 28%. Among these
atients, 40% were functional class III or IV. At five years,
0% of patients continued to have signs and symptoms of
HF, demonstrating the limitations of CABG surgery
lone (32). Another study of CABG for ischemic cardio-
yopathy confirmed that recurrent CHF was the most
ommon cause of death postoperatively (27).
itral valve repair or replacement. Functional mitral
egurgitation often accompanies ventricular dilation (33).
atients with ischemic cardiomyopathy undergoing mitral
rocedures have a five-year mortality of approximately 50%
27,34). Recurrence of CHF occurs in one-third of patients
y five years and is the most common cause of death,
resumably related to continuing dysfunction of the un-
odified ventricle (27,35). Mitral valve repair is an integral
art of the SVR procedure in addition to volume reduction
nd revascularization.
entricular assist or replacement. Other surgical ap-
roaches in the treatment of ischemic cardiomyopathy
nclude LVAD and transplantation. The Randomized Eval-
igure 6. Survival based upon preoperative New York Heart Association
unctional class.ation of Mechanical Assistance for the Treatment of
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SVR for Ischemic Dilated Cardiomyopathy October 6, 2004:1439–45ongestive Heart Failure (REMATCH) trial examined
VAD use as long-term myocardial replacement therapy in
atients who were ineligible for cardiac transplantation.
ess than 10% of patients survived to three years in the
VAD group, compared with no survivors among patients
reated medically (36). The five-year survival after cardiac
ransplantation is 70%, but few patients receive a heart
wing to donor shortage (37). The five-year survival of
YHA functional class IV patients undergoing SVR in our
egistry was approximately 50%. Surgical ventricular resto-
ation should be considered as a therapeutic option because
t can be more readily applied compared with LVAD or
ransplantation.
VR. The SVR was applied to patients with previous
nfarctions primarily as therapy for advanced heart failure.
he few patients with less advanced symptoms of CHF,
amely NYHA functional class I or II, underwent SVR as
concomitant procedure to CABG or mitral valve repair
ased on the important recognition that volume, not EF, is
he major determinant of survival after myocardial infarc-
ion. White et al. showed that patients with LVESVI 60
l/m2 have approximately a fivefold increase in mortality
ompared with those with normal volumes after infarction
6). The GUSTO I trial similarly demonstrated the impor-
ance of ventricular volume on outcome. Among infarction
atients with successful thrombolysis, 17% had progressive
V enlargement above 40 ml/m2. Mortality at one year was
6% among those with LVESVI 40 to 50 ml/m2, 21% with
VESVI 50 to 60 ml/m2, and 33% with LVESVI 60
l/m2 (3). A small number of patients (9%) in functional
lass I underwent restoration as an adjunct to CABG
ecause ventricular dilation (LVESVI 60 ml/m2) is a
recursor of late development of CHF and early death (3).
ore importantly, the low five-year mortality of patients
ith NYHA functional class II and III symptoms of CHF,
nd LVESVI 120 ml/m2 further define the importance of
sing volume measurement to gauge the progression of
HF and how LVESVI helps determine prognosis.
Our multivariate analysis of SVR shows that major risk
actors were age, preoperative EF, LVESVI, and NYHA
unctional class. The five-year survival of 63% among
atients 75 years old is a gratifying result in view of the
act that CHF is common in the elderly. Mitral valve
rocedures were performed in over 20% of patients in this
eries and were more common in patients with severely
epressed systolic function and extensive ventricular dila-
ion. Regurgitation was usually central and thus amenable to
ing annuloplasty. Subgroup analysis showed patients with
itral repair had larger hearts from secondary mitral regur-
itation, and sustained greater improvement in LVESVI
hen valve repair was added to CABG and SVR. The rare
se (1%) of mitral valve replacement was indicated be-
ause of previous infarcted segments in sites other than the
ntero-apical or antero-septal regions. These patients were a
igh-risk group, and our findings are consistent with the
eport by Di Donato et al. (38) of decreased survival at twoears (52%) if the muscle remote from the anterior scar was
synergic. These findings illustrate the importance of pre-
perative assessment of the non-infarcted segments supplied
y the right and circumflex arteries. Imaging of the remote
uscle is crucial, and SVR should be avoided if the inferior
nd lateral wall segments are infarcted and asynergic (19).
ypokinesia, however, is not a contraindication to opera-
ion, because local contractility may improve with revascu-
arization. Viability of remote segments is helpful in deter-
ining operability.
tudy limitations. This was a non-randomized registry of
atients who underwent the SVR procedure. Drug regimens
ere not standardized or reported. Quality of life was based
n NYHA functional class. Criteria for CHF hospital
dmission may have varied among centers.
Although the overall geometric objective was similar,
ome centers used direct closure in selected cases, and others
laced an endocardial patch in all patients. Myocardial
rotection varied. The indication for intra-aortic balloon
umping use was not specified. Measurements of EF and
VESVI were performed by the same method in each
atient before hospital discharge; however, the interval
etween operation and these measurements was not stan-
ardized. Implantable defibrillators were not routinely
laced in these patients, and arrhythmia management in the
ESTORE registry varied. In most instances, preoperative
lectrophysiologic testing was not performed.
onclusions. Surgical ventricular restoration reduces vol-
me and “restores” a more normal elliptical ventricular
hape in dilated hearts after anterior infarction. Our data
emonstrate a low operative mortality, improved systolic
unction, a gratifying five-year survival, and a low rate of
ehospitalization for CHF.
Our previous results were instrumental in the design of
he current Surgical Treatment for Ischemic Heart Failure
STICH) trial that randomizes patients with ischemic
ardiomyopathy to medical therapy, CABG alone, or
ABG with SVR. The RESTORE groups’ outcomes serve
s a benchmark for this trial, which should further define
he optimal indications for ventricular restoration.
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